Pogo, May 5, 2020. Under the $2 trillion coronavirus relief law, makers of over-the-counter drugs will pay the FDA to oversee their products and will gain new sway over the consumer protection agency.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
What You Need to Know About the Malaria Drugs Trump Keeps Touting
Politico: April 6, 2020. The Trump administration is pushing ahead with a plan to “surge” the malaria drug hydroxychloroquine to coronavirus hot zones around the country, despite clear harms, including blindness and heart failure, and interactions with common medications.
Read More »FDA Grants Experimental Coronavirus Drug Benefits For Rare Disease Treatments
NPR, March 25, 2020. FDA gives possible new drug to treat coronavirus orphan drug status, despite the fact that more than 200,000 people will ultimately get coronavirus.
Read More »Here’s how to get a coronavirus test in New York City if you’re feeling sick
Business Insider, March 20, 2020. With the rise of coronavirus cases across the United States, the demand for testing is rapidly increasing. Unfortunately, those with more fame and money are more likely to gain access to testing due to this shortage.
Read More »‘Bad advice from the president’: Trump touts unproven coronavirus drugs
Politico: March 20, 2020. We find that the president’s suggested programs allowing the administration to get experimental drugs to people quickly outside of clinical trials is bad advice.
Read More »